	DISCOVERY COHORT						VALIDATION COHORT					
	SSc-PAH			SSc-no PAH			SSc-PAH			SSc-no PAH		
	N			N			N			N		
Sex (female), n (%)	15	14	(93%)	16	14	(88%)	24	17	(71%)	17	15	(88%)
Age (yo), mean (±SD)	15	65	(±7)	16	50	(±14)	24	68	(±9)	17	67	(±7)
ANA, n (%)	13	13	(100%)	14	14	(100%)	17	17	(100%)	14	14	(100%)
- ACA, n (%)	12	9	(75%)	9	4	(44%)	8	7	(88%)	14	10	(71%)
- ATA, n (%)	12	0	(0%)	9	1	(11%)	8	0	(0%)	14	4	(29%)
- Anti-U1RNP, n (%)	12	1	(8%)	9	2	(22%)	8	0	(0%)	14	0	(0%)
Disease duration												
- since RP onset (y), mean (±SD)	10	19	(±13)	11	13	(±13)	8	18	(±12)	15	24	(±17)
- since first non-RP symptom onset (y), median [Q1;Q3]	8	8	[2;13]	10	10	[3;12]	6	7	[0;17]	14	7	[4;10]
- since diagnosis (y), median [Q1;Q3]	15	1.25	[0.05;6]	16	7	[1;11]	9	0.5	[0;9]	6	7	[3;13]
BMI (kg/m²), mean (±SD)	15	28	(±4)	15	24	(±5)	16	28	(±6)	14	25	(±4)
mRSS, median [Q1;Q3]	5	3	[2;5]	9	3	[2;5]	7	3	[3;5]	14	6	[3;8]
NYHA functional class	15			8			18			4		
- class I, n (%)		0	(0%)		8	(100%)		0	(0%)		2	(50%)
- class II, n (%)		7	(47%)		0	(0%)		6	(33%)		2	(50%)
- class III, n (%)		8	(53%)		0	(0%)		10	(56%)		0	(0%)
- class IV, n (%)		0	(0%)		0	(0%)		2	(11%)		0	(0%)
BNP (pg/mL), median [Q1;Q3]	12	147	[69;505]	2	25	[24;27]	14	84	[39;264]			
Nt-pro-BNP (pg/mL), median [Q1;Q3]							14	727	[319;1098]	5	126	[88;134]
eGFR (mL/min/1.73m²), mean (±SD)	12	68	(±15)	7	78	(±21)	16	82	(±20)	15	74	(±16)
LVEF (%), mean (±SD)	12	60	(±9)	11	64	(±6)	14	65	(±9)	15	63	(±6)
Estimated sPAP (mmHg), mean (±SD)	12	72	(±19)	7	26	(±5)	15	59	(±16)	10	28	(±4)
FVC (% predicted), mean (±SD)	13	85	(±10)	16	110	(±15)	20	88	(±18)	13	111	(±14)
DLCO (% predicted), median [Q1;Q3]	15	35	[8;52]	16	92	[87;109]	10	41	[33;65]	12	65	[59;82]

ILD on CT-scan, n (%)	15	6	(40%)	16	0	(0%)	24	5	(21%)	17	6	(35%)	
Treatments													
- Prednisone, n (%)	15	0	(0%)	16	2	(13%)	16	1	(6%)	15	0	(0%)	
- Cyclophosphamide, n (%)	15	0	(0%)	16	0	(0%)	16	0	(0%)	15	0	(0%)	
- Mycophenolate mofetil, n (%)	15	0	(0%)	16	1	(6%)	16	0	(0%)	15	0	(0%)	
- D-penicillamine, n (%)	15	0	(0%)	16	0	(0%)	16	2	(13%)	15	0	(0%)	
- Azathioprine, n (%)	15	0	(0%)	16	0	(0%)	16	0	(0%)	15	0	(0%)	
- Methotrexate, n (%)	15	0	(0%)	16	1	(6%)	16	1	(6%)	15	0	(0%)	
Right-heart catheterization													
- mPAP (mmHg), mean (±SD)	15	44	(±10)	/	/	/	24	37	(±8)	/	/	/	
- PAWP (mmHg), mean (±SD)	15	10	(±2)	/	/	/	24	10	(±3)	/	/	/	
- CO (L/min), mean (±SD)	15	4.9	(±1.6)	/	/	/	24	4.6	(±1.2)	/	/	/	
- CI (L/min/m²), mean (±SD)	15	2.7	(±1.0)	/	/	/	18	2.5	(±0.5)	/	/	/	
- PVR (WU), mean (±SD)	15	8.5	(±5.0)	/	/	/	24	6.2	(±2.3)	/	/	/	

¶

Supplementary Table 1. Detailed characteristics of patients from the discovery and validation cohorts

ACA: anti-centromere antibodies; ANA: antinuclear antibodies; ATA: anti-topoisomerase I antibodies; Anti-U1RNP: anti-U1-ribonucleoprotein antibodies; BMI: body-mass index; BNP: brain natriuretic peptide; CI: cardiac index; CO: cardiac output; DLCO: diffusing capacity of the lung for carbon monoxide; eGFR: estimated glomerular filtration rate; FVC: forced vital capacity: ILD: interstitial lung disease: LVEF: left ventricular ejection fraction; mPAP: mean pulmonary arterial pressure; Nt-pro-BNP: N-terminal pro-brain natriuretic peptide; NYHA: New York Heart Association; PAH: pulmonary arterial hypertension; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular resistance; Q: quartile; RP: Raynaud phenomenon; SD: standard deviation; sPAP: systolic pulmonary arterial pressure; SSc: systemic sclerosis; WU: Wood unit; y: year; yo: year old.